Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study - PubMed (original) (raw)
Clinical Trial
Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study
L S Schneider et al. Alzheimer Dis Assoc Disord. 1997.
Abstract
This article reports the development and psychometric properties of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC). At present, a number of unvalidated CGIC scales are used in clinical trials, with various methods for making ratings. The ADCS-CGIC was designed on the basis of a survey of ADCS clinicians and by adapting existing instruments. It includes an organized but unstructured format, with which a clinician can address clinically relevant change. The instrument's reliability and validity were assessed in a prospective trial of Alzheimer's disease (AD) and healthy subjects over a 12-month period. It showed good short-term reliability at 1 and 2 months, with 90 and 94% of AD subjects, respectively, rated as having changed not at all or only minimally. The ADCS-CGIC's face validity was demonstrated by untreated. AD subjects rated as having worsened over time at both 6 months (56% rated as having worsened) and 12 months (81% rated as having worsened), whereas only 2% of control subjects showed minimal worsening. As a measure of predictive validity, ADCS-CGIC ratings at 12 months were significantly associated with change on four severity scales. As with other measures, change ratings were sensitive to dementia severity. Moderately impaired subjects showed greater worsening than other subjects. ADCS-CGIC ratings of greater worsening were made after the informant interview, regardless of whether informants or subjects were interviewed first. The ADCS-CGIC is a valid and reliable instrument for use in clinical trials.
Similar articles
- ADCS Prevention Instrument Project: ADCS-clinicians' global impression of change scales (ADCS-CGIC), self-rated and study partner-rated versions.
Schneider LS, Clark CM, Doody R, Ferris SH, Morris JC, Raman R, Reisberg B, Schmitt FA. Schneider LS, et al. Alzheimer Dis Assoc Disord. 2006 Oct-Dec;20(4 Suppl 3):S124-38. doi: 10.1097/01.wad.0000213878.47924.44. Alzheimer Dis Assoc Disord. 2006. PMID: 17135806 - Clinical evaluation of global change in Alzheimer's disease: identifying consensus.
Olin JT, Schneider LS, Doody RS, Clark CM, Ferris SH, Morris JC, Reisberg B, Schmitt FA. Olin JT, et al. J Geriatr Psychiatry Neurol. 1996 Oct;9(4):176-80. doi: 10.1177/089198879600900404. J Geriatr Psychiatry Neurol. 1996. PMID: 8970010 - Clinical global impressions in Alzheimer's clinical trials.
Schneider LS, Olin JT. Schneider LS, et al. Int Psychogeriatr. 1996 Summer;8(2):277-88; discussion 288-90. doi: 10.1017/s1041610296002645. Int Psychogeriatr. 1996. PMID: 8994897 Review. - Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis.
Cummings JL, Ferris SH, Farlow MR, Olin JT, Meng X. Cummings JL, et al. Dement Geriatr Cogn Disord. 2010;29(5):406-12. doi: 10.1159/000296073. Epub 2010 May 21. Dement Geriatr Cogn Disord. 2010. PMID: 20502014 Clinical Trial. - Review of outcome measurement instruments in Alzheimer's disease drug trials: psychometric properties of global scales.
Oremus M, Perrault A, Demers L, Wolfson C. Oremus M, et al. J Geriatr Psychiatry Neurol. 2000 Winter;13(4):197-205. doi: 10.1177/089198870001300404. J Geriatr Psychiatry Neurol. 2000. PMID: 11128059 Review.
Cited by
- Feasibility and Preliminary Efficacy of American Elderberry Juice for Improving Cognition and Inflammation in Patients with Mild Cognitive Impairment.
Curtis AF, Musich M, Costa AN, Gonzales J, Gonzales H, Ferguson BJ, Kille B, Thomas AL, Wei X, Liu P, Greenlief CM, Shenker JI, Beversdorf DQ. Curtis AF, et al. Int J Mol Sci. 2024 Apr 15;25(8):4352. doi: 10.3390/ijms25084352. Int J Mol Sci. 2024. PMID: 38673938 Free PMC article. Clinical Trial. - Randomized controlled trial of propranolol on social communication and anxiety in children and young adults with autism spectrum disorder.
Beversdorf DQ, Ferguson B, Hunter S, Hirst K, Lolli B, Bellesheim KR, Barton AU, Muckerman J, Takahashi N, Selders K, Holem R, Sohl K, Dyke P, Stichter J, Mazurek M, Kanne S. Beversdorf DQ, et al. Psychopharmacology (Berl). 2024 Jan;241(1):19-32. doi: 10.1007/s00213-023-06452-1. Epub 2023 Dec 13. Psychopharmacology (Berl). 2024. PMID: 38086927 Clinical Trial. - Remotely supervised at-home delivery of taVNS for autism spectrum disorder: feasibility and initial efficacy.
Black B, Hunter S, Cottrell H, Dar R, Takahashi N, Ferguson BJ, Valter Y, Porges E, Datta A, Beversdorf DQ. Black B, et al. Front Psychiatry. 2023 Sep 28;14:1238328. doi: 10.3389/fpsyt.2023.1238328. eCollection 2023. Front Psychiatry. 2023. PMID: 37840787 Free PMC article. - Efficacy of transcutaneous auricular vagus nerve stimulation on radiotherapy-related neuropathic pain in patients with head and neck cancers (RELAX): protocol for a multicentre, randomised, double-blind, sham-controlled trial.
Zuo X, Li Y, Rong X, Yang X, Zhu Y, Pan D, Li H, Shen QY, Tang Y. Zuo X, et al. BMJ Open. 2023 Sep 20;13(9):e072724. doi: 10.1136/bmjopen-2023-072724. BMJ Open. 2023. PMID: 37730386 Free PMC article. - Effects of methylphenidate on neuropsychiatric symptoms in Alzheimer's disease: Evidence from the ADMET 2 study.
Clark ED, Perin J, Herrmann N, Brawman-Mintzer O, Lanctôt KL, Lerner AJ, Mintzer J, Padala PR, Rosenberg PB, Sami S, Shade DM, van Dyck CH, Porsteinsson AP; ADMET‐2 Study Group. Clark ED, et al. Alzheimers Dement (N Y). 2023 Aug 2;9(3):e12403. doi: 10.1002/trc2.12403. eCollection 2023 Jul-Sep. Alzheimers Dement (N Y). 2023. PMID: 37538343 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Other Literature Sources
Medical
Research Materials